Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsSTU:01P -0.86%91 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates STU:01P with a GF Score™ of 91/100 and a GF Value™ of €469.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 1075267.74% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Medpace Holdings's
Operating Income
for the
three
months ended in Jun. 2026 was €126 Mil. Medpace Holdings's Interest Expense for the
three
months ended in Jun. 2026 was €0 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Medpace Holdings Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Medpace Holdings's Interest Coverage or its related term are showing as below:
STU:01P's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.22 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Medpace Holdings Interest Coverage Related Terms
Medpace Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:01P vs RVTY, CRL, ICLR: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GuruFocus does not calculate Medpace Holdings's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Medpace Holdings (STU:01P) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Medpace Holdings and its competitors. Over the past decade, Medpace Holdings' Interest Coverage has ranged from 2.71 to 1,891.57. According to the industry distribution chart, Medpace Holdings ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry.
Is Medpace Holdings' Interest Coverage too high?
Medpace Holdings' current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 1,891.57. Based on the distribution chart, Medpace Holdings ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Interest Coverage compare to RVTY and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #999999 out of 93 companies for Interest Coverage. This places Medpace Holdings in the lower half of its industry. The industry median Interest Coverage is 10.22. Historically, Medpace Holdings' own Interest Coverage has ranged from 2.71 to 1,891.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 10.22, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 10.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (STU:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €469.57, compared to a current price of €531.80 — trading 13.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Medpace Holdings' overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Medpace Holdings (STU:01P), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (STU:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €531.80 is trading 13.3% above its estimated GF Value™ of €469.57.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for STU:01P:
Interest Coverage: 0 (At Loss)
GF Value™: €469.57 vs. price of €531.80 (13.3% above fair value)
No single metric tells the full story. See the STU:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
91GF Score
Get the complete analysis for STU:01P
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:01P has been successfully added to your 
